Results 381 to 390 of about 15,014,800 (402)

Shifting institutional culture to develop climate solutions with Open Science. [PDF]

Ecol Evol
Lowndes JS, Holder AM, Markowitz EH, Clatterbuck C, Bradford AL, Doering K, Stevens MH, Butland S, Burke D, Kross S, Hollister JW, Stawitz C, Siple MC, Rios A, Welch JN, Li B, Nojavan F, Davis A, Steiner E, London JM, Fenwick I, Hunzinger A, Verstaen J, Holmes E, Virdi M, Barrett AP, Robinson E.   +26 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Integrating open education practices with data analysis of open science in an undergraduate course. [PDF]

Ecol Evol
Bakermans MH.
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

The effects of listening on speaker and listener while talking about character strengths: an open science school-wide collaboration. [PDF]

R Soc Open Sci
Moin T, Weinstein N, Itzchakov G, Branson A, Law B, Yee L, Pape E, Cheung RYM, Haffey A, Chakrabarti B, Beaman P.   +10 more
europepmc   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

CATEcor: An Open Science, Shaded-Truss, Externally-Occulted Coronagraph. [PDF]

Sol Phys
DeForest C, Seaton DB, Caspi A, Beasley M, Davis SJ, Erickson NF, Kovac SA, Patel R, Tosolini A, West MJ.   +9 more
europepmc   +1 more source

Accelerating progress in cardiology: embracing open science. [PDF]

Open Heart
Meier P.
europepmc   +1 more source

Implementing open science and reproducible research practices in mental health research through registered reports. [PDF]

JCPP Adv
Baldwin JR, Larsson H.
europepmc   +1 more source

The Open Force Field Initiative: Open Software and Open Science for Molecular Modeling. [PDF]

J Phys Chem B
Wang L, Behara PK, Thompson MW, Gokey T, Wang Y, Wagner JR, Cole DJ, Gilson MK, Shirts MR, Mobley DL.   +9 more
europepmc   +1 more source